Adalank is marketed as a stabilized or modified analogue of Selank, a synthetic peptide originally investigated for anxiolytic and neuroactive effects. However, the public scientific record for Adalank itself is extremely limited, and claims about its properties are largely extrapolated from Selank rather than supported by dedicated Adalank studies.

Product Information

Unlike Selank, which has a defined peptide sequence and a published research record, Adalank does not currently have a clearly documented independent sequence, pharmacokinetic profile, or clinical-trial literature under that name. A 2026 database review reported no PubMed records specifically indexed under “Adalank.”

How It Works

A validated mechanism for Adalank has not been established. Proposed mechanisms are generally borrowed from Selank research, including potential effects on neurotrophic and neurotransmitter-related pathways, but these mechanisms should not be assumed to apply identically to an analogue whose structure has not been independently characterized.

POTENTIAL BENEFITS

1. Selank-Analogue Research

Adalank is primarily relevant to research examining whether structural modification of Selank can alter stability, duration, or biological activity. This is currently a proposed research rationale rather than a clinically demonstrated advantage.

2. Neurotrophic Research

Selank research has investigated neurotrophin-related signaling, including BDNF pathways. These findings provide background for Adalank research, but direct evidence for Adalank itself remains limited.

3. Cognitive Research

Modified Selank analogues are of interest in research into attention, memory, stress response, and cognitive signaling. However, these areas remain substantially better documented for Selank than for Adalank.

4. Peptide-Stability Research

The primary claimed distinction of Adalank is improved stability compared with Selank. Because independent stability studies are not publicly established, this remains an important area for future characterization.

Dosage

There is no established human dosage for Adalank. Some commercial sources publish microgram-level protocols, but these are vendor claims rather than validated clinical dosing data. The absence of dedicated human trials means Selank dosing should not simply be transferred to Adalank.

Side Effects

A reliable human safety profile has not been established for Adalank. The lack of dedicated clinical studies means its tolerability, pharmacokinetics, metabolism, and long-term effects remain uncertain.

References

1. Adalank — literature and PubMed evidence review
2. Adalank commercial research profile and claimed protocols
3. Selank research — PubMed
4. Selank and neurotrophic-factor research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

REM Blend is a sleep-oriented research formulation combining DSIP, Pinealon, melatonin, and GABA. The combination brings together peptide and non-peptide ingredients investigated in sleep, circadian, neurological, and relaxation research.

Product Information

Current research-market listings describe a REM Blend containing approximately DSIP 10 mg + Pinealon 10 mg + melatonin 50 mg + GABA 250 mg in 10 mL. Importantly, formulations sold under the REM Blend name can vary, so the actual composition should always be verified from the product specification.

How It Works

The formulation combines different sleep-related pathways. DSIP and Pinealon are research peptides, while melatonin participates directly in circadian signaling and GABA is the brain's primary inhibitory neurotransmitter.

POTENTIAL BENEFITS

1. Sleep Research

DSIP has historically been investigated for its relationship with sleep architecture and delta-wave activity. The peptide provides the primary sleep-focused research component of the blend.

2. Circadian Research

Melatonin is an established regulator of circadian timing and sleep-wake signaling. Its inclusion makes the formulation relevant to research examining biological-clock regulation.

3. Neuroendocrine Research

Pinealon has been investigated in cellular and animal research involving brain function, oxidative stress, and age-associated biological changes. Its presence broadens the blend into neuroendocrine and cellular-aging research.

4. GABAergic Research

GABA is the principal inhibitory neurotransmitter in the central nervous system. Research involving GABA-related signaling provides an additional pathway for investigating neuronal relaxation and sleep-related physiology.

Dosage

There is no standardized clinical dosage for REM Blend. Current listings describe different formulations and concentrations, and the combination itself has not been clinically validated as a single standardized preparation.

Side Effects

Potential effects depend on the individual ingredients and their concentrations. Melatonin and GABA can cause drowsiness, while the human safety evidence for DSIP/Pinealon combinations is limited. The complete blend has not undergone controlled clinical safety evaluation.

References

1. Sleep and circadian peptide-stack research, including REM Blend composition
2. DSIP research — PubMed
3. Pinealon research — PubMed
4. Melatonin and sleep/circadian research — PubMed
5. GABA and sleep research — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

N-Acetyl Epithalon Amidate is a modified form of Epithalon. It is a synthetic tetrapeptide that is studied in relation to compounds derived from the pineal gland. This version includes both N-acetylation and C-terminal amidation, structural changes that enhance peptide stability and resistance to enzymatic breakdown. Due to these modifications, the compound is often utilized in research settings for studying peptide structure, stability, and interactions within biological systems.

In experimental studies, N-Acetyl Epithalon Amidate has been investigated for its role in cellular and molecular processes. Research has particularly focused on its effects on telomere regulation, oxidative stress pathways, and cellular signaling. Research also shows its involvement in epigenetic mechanisms and its influence on cellular differentiation models.

Working Mechanism of N-Acetyl Epithalon Amidate

N‑Acetyl Epithalon Amidate, like its parent peptide Epithalon, is studied primarily for its influence on cellular aging pathways in experimental systems. Research indicates it may interact with mechanisms that regulate telomerase expression. This interaction potentially supports maintenance of telomere length through upregulation of the catalytic telomerase subunit in treated cell cultures, a process associated with chromosomal stability. 

It has also been investigated for effects on oxidative stress pathways and gene expression modulation in vitro. In research studies, changes in antioxidant enzyme activity and cell signaling have been observed.

Chemical Properties of N-Acetyl Epithalon Amidate 

• CAS Number: 307297-39-8
• Molar Mass: 390.35 g·mol⁻¹
• Chemical Formula: C14H22N4O9
• IUPAC Name: (4S)-4-[[(2S)-2-aminopropanoyl]amino]-5-[[(2S)-3-carboxy-1-(carboxymethylamino)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid

Note: For more research compounds, be sure to explore our selection of Nasal Sprays, including other unique products like MOTS-C Nasal Spray and N-Acetyl Semax Amidate Nasal Spray for further research advancements.

Research Findings on N-Acetyl Epithalon Amidate

In controlled laboratory studies, the tetrapeptide related to Epithalon has been shown to influence telomere dynamics in cell cultures. Treatment of mammalian cell lines increased telomerase activity and extended telomere length. Analyses using qPCR and telomerase assays showed dose‑dependent rises in telomere length and enzyme expression. These results suggest a role in telomere maintenance under experimental conditions.

Research has also studied its effects on antioxidant and cellular stress pathways. In aging cell models, peptide exposure reduced intracellular reactive oxygen species. It also affected mitochondrial function, including changes in membrane potential. Indicators of oxidative damage decreased, showing impacts on cellular stress and redox regulation in vitro.

Note: This compound is not approved by the FDA for medical use. It is intended for research purposes only.

BehemothLabz Disclaimer

Please make sure you go through the Terms and Conditions, and please familiarize yourself with them as they are important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.

You are welcome to review our Terms and Conditions. If you have questions about a listed product, reach us at support@behemothlabz.com.

ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.

Reference Links

• Al-dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5). https://doi.org/10.1007/s10522-025-10315-x
• Yue, X., Liu, S.-L., Guo, J.-N., Meng, T.-G., Zhang, X.-R., Li, H.-X., Song, C.-Y., Wang, Z.-B., Schatten, H., Sun, Q.-Y., & Guo, X.-P. (2022). Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging, 14(7), 3191–3202. https://doi.org/10.18632/aging.204007

Mod GRF 1-29, also called CJC-1295 No DAC, is a synthetic peptide made from 29 amino acids. It is studied as a growth hormone-releasing hormone (GHRH) analog in laboratory settings.

This is similar to LGD-4033, which has unique characteristics. It may be able to pass through the blood-brain barrier, according to studies. Most of the material that is currently available on this subject comes from studies on animals. These models showed alterations in tissue responsiveness and bone density under controlled settings.

It is also available in lyophilized peptide form for other types of research setups. This product is for laboratory research use only and is not approved for human or veterinary use.

Mechanism of Action

Mod GRF 1-29's interaction with growth hormone-releasing hormone receptors is investigated in research settings.

In experimental animals, it may affect signaling pathways linked to the release of growth hormone after binding. To comprehend timing, pulse release patterns, and receptor response behavior, these routes are investigated.

It is frequently utilized in studies evaluating the stability and duration of action of different peptide variants due to its shorter structure and lack of DAC modification.

Properties of Mod GRF 1-29

• Molecular Formula: C149H246N44O42
  
• Molecular Weight: 3357.93 g/mol
  
• CAS Number: 86168-78-7
  
• PubChem CID: 16132343
  
• IUPAC Name: L-tyrosyl-L-alanyl-L-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucylglycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide
  
• Synonyms: Mod GRF 1-29, CJC-1295 No DAC, GRF (1-29)
  

Research Applications

GHRH Receptor Interaction Studies

Mod GRF 1-29 is used to study how peptides bind to GHRH receptors in controlled models. Research focuses on receptor activation and signaling response. [1]

Growth Hormone Signaling Research

Studies examine how this peptide may influence growth hormone-related pathways, including pulse release behavior and timing in experimental systems. [2]

Peptide Stability and Duration Studies

Because it does not include DAC, it is used to compare shorter-acting peptides with extended-release versions. This helps in studying stability and activity duration. [1]

Intranasal Delivery Research

The nasal spray format is included in studies exploring peptide transport through intranasal routes. This supports research on absorption and delivery behavior. [3]

References

• Rekasi, Z., et al. Structure and function of GHRH analogs. Endocrine Reviews (2000).
• Bowers, C. Y. Growth hormone-releasing hormone analogs and activity studies. Peptides (1998).
• Illum, L. Intranasal delivery of peptides and proteins. Journal of Controlled Release (2000).

Melanotan 1 is the name commonly associated with afamelanotide, a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It has been studied extensively for stimulating melanin production and increasing pigmentation, including in photodermatological research.

Product Information

Afamelanotide is designed to activate melanocortin receptors and increase eumelanin production. Unlike Melanotan II, it was developed with a stronger clinical focus on photoprotection and pigmentation disorders and has been evaluated in randomized human trials.

How It Works

Afamelanotide activates melanocortin receptors on melanocytes, stimulating melanogenesis and increasing melanin production. The resulting pigmentation can provide a degree of endogenous photoprotection by increasing the skin's melanin content.

POTENTIAL BENEFITS

1. Melanin Production Research

Afamelanotide has demonstrated measurable increases in skin pigmentation in controlled human studies. This makes it one of the more clinically studied melanocortin analogues.

2. Photoprotection Research

Research has investigated whether increased melanin production can reduce the severity of UV-related phototoxic reactions. This has been particularly relevant in erythropoietic protoporphyria and solar urticaria.

3. Pigmentation Research

Afamelanotide has been studied in disorders involving abnormal pigmentation, including vitiligo. Clinical trials have examined its use alongside narrowband UV-B phototherapy.

4. Melanocortin Research

Melanotan 1 provides a well-characterized model for studying α-MSH-related melanocortin signaling, melanocyte activity, and the relationship between pigmentation and UV response.

Dosage

Clinical studies of afamelanotide have used 16 mg subcutaneous implants, including monthly administration in some photodermatology protocols. This information relates specifically to the clinically developed implant formulation and should not be transferred to unapproved Melanotan 1 preparations. (pubmed.ncbi.nlm.nih.gov)

Side Effects

Clinical studies have reported injection/implant-site reactions, nausea, headache, fatigue, and increased pigmentation. Freckling and darkening of existing pigmented lesions can also occur as melanogenesis increases.

References

1. Harms J, et al. *Afamelanotide for Erythropoietic Protoporphyria.* N Engl J Med.
2. Grimes PE, et al. *Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo.* JAMA Dermatol.
3. Systemic photoprotection in solar urticaria with afamelanotide.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.

HGH Fragment 176-191 is a 16-amino-acid C-terminal fragment of human growth hormone (hGH). It has attracted research interest because certain C-terminal GH fragments have demonstrated effects on lipid metabolism and fat oxidation in experimental models.

Product Information

The native hGH 176-191 fragment should be distinguished from AOD-9604, a related but chemically distinct GH-derived peptide that has been studied in humans. Most of the commonly cited fat-loss literature belongs to AOD-9604 or other GH fragments rather than the native 176-191 sequence itself.

How It Works

Preclinical research has investigated C-terminal GH fragments for effects on lipid metabolism, including lipolysis and fat oxidation. The mechanism is distinct from full-length growth hormone and does not simply reproduce the complete GH/IGF-1 signaling profile.

POTENTIAL BENEFITS

1. Lipolysis Research

C-terminal GH-fragment research has examined whether specific portions of the hormone can influence the breakdown of stored fat. Animal studies have provided the primary evidence supporting this research direction.

2. Fat-Oxidation Research

Experimental studies have investigated increased fatty-acid utilization following exposure to GH-derived fragments. These findings have helped drive interest in the fragment as a model for selective metabolic signaling.

3. Metabolic Research

The fragment provides a way to investigate biological activity within a specific region of the larger GH molecule. This is useful for studying whether metabolic effects can occur independently of full-length GH activity.

4. GH-Fragment Research

HGH Fragment 176-191 is particularly relevant to structure-function research examining how different regions of growth hormone contribute to biological effects. Evidence for the native fragment itself remains predominantly preclinical.

Dosage

There is no established human dosage for native HGH Fragment 176-191. Published human clinical research commonly associated with this peptide concerns the related compound AOD-9604, which should not be treated as identical to the native 176-191 sequence. Animal doses therefore should not be presented as validated human dosing.

Side Effects

Human safety data for native HGH Fragment 176-191 are insufficient. Because the exact fragment has not undergone a meaningful clinical development program, its human pharmacokinetics, tolerability, and long-term safety remain incompletely characterized.

References

1. Ng FM, et al. *Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.*
2. Ng FM, et al. Research on C-terminal growth hormone fragments and metabolic activity.
3. AOD-9604 and GH-fragment human research review.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Retatrutide is one of the most closely watched metabolic peptides in current research. Its unique ability to target three hormone receptors at once — GLP-1, GIP, and glucagon — has generated significant interest around weight management, appetite regulation, and metabolic health.

Product Information

Retatrutide is a triple agonist designed to act on three complementary metabolic pathways. Clinical trials have reported substantial weight reduction alongside improvements in glycemic and other metabolic measures.

How It Works

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors. GLP-1 and GIP pathways influence appetite and glucose regulation, while glucagon signaling is associated with energy expenditure and metabolic fuel utilization. Together, these pathways create retatrutide's distinctive triple-action profile.

Potential Benefits

1. Supports Weight-Loss Research

Retatrutide has demonstrated significant dose-dependent weight reduction in clinical studies, making it one of the most closely watched metabolic peptides.

2. Appetite Regulation

Its GLP-1 and GIP activity is closely connected with appetite and food-intake regulation.

3. Blood-Glucose Research

Clinical research has shown improvements in HbA1c and other glucose-related measures.

4. Energy Expenditure

The glucagon component of retatrutide is believed to contribute to increased energy expenditure and altered fuel utilization.

5. Metabolic Health

Research has explored retatrutide's effects on triglycerides, liver fat and other markers associated with metabolic health.

Dosage

Clinical retatrutide research has primarily involved once-weekly subcutaneous administration, with studies evaluating escalating doses up to 12 mg.

For the intranasal formulation, there is currently no clinically established equivalent nasal dosage. Therefore, intranasal amounts reported online should be regarded as formulation-specific market information rather than established clinical dosing.

Side Effects

Common adverse effects reported in clinical retatrutide research include nausea, vomiting, diarrhea, and constipation, with gastrointestinal effects becoming more common at higher doses.

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37366315. PubMed

Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. PMID: 37385280. PubMed

Retatrutide is a once-weekly investigational peptide designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon. It has been extensively studied in clinical trials for obesity and metabolic disease.

Product Information

Retatrutide combines three complementary receptor activities within a single molecule. GLP-1 and GIP signaling can influence appetite, glucose regulation, and insulin secretion, while glucagon signaling can increase energy expenditure and influence hepatic metabolism.

How It Works

Retatrutide activates the GIP, GLP-1, and glucagon receptors. This triple-agonist activity is intended to combine appetite and glucose-regulatory effects with glucagon-mediated metabolic activity.

POTENTIAL BENEFITS

1. Weight-Loss Research

In a phase 2 randomized trial involving adults with overweight or obesity, retatrutide produced substantial body-weight reductions over 48 weeks. The study established significant dose-dependent weight-loss signals worthy of continued clinical investigation.

2. Metabolic Research

Retatrutide has been studied for effects on body weight, glucose regulation, insulin sensitivity, and other metabolic markers. Its multi-receptor mechanism makes it distinct from single- and dual-agonist approaches.

3. Appetite-Regulation Research

GLP-1 and GIP receptor activity can influence appetite and food intake, while glucagon activity contributes to energy metabolism. Retatrutide therefore provides a research model for investigating multiple pathways controlling energy balance.

4. Triple-Agonist Research

The defining feature of retatrutide is its simultaneous activation of three hormone receptors. This provides an important platform for studying whether coordinated GIP, GLP-1, and glucagon signaling can produce greater metabolic effects than single-pathway activation.

Dosage

The phase 2 obesity trial studied once-weekly retatrutide doses ranging from 1 mg to 12 mg, using different dose-escalation schedules. These were clinical-trial protocols, not an established general-use dosing regimen. Gastrointestinal adverse events were among the most common treatment-emergent effects. (pubmed.ncbi.nlm.nih.gov)

Side Effects

The phase 2 study reported gastrointestinal adverse events, particularly nausea, diarrhea, and vomiting. Heart-rate increases were also observed. The ongoing clinical development program continues to evaluate longer-term safety and efficacy.

References

1. Jastreboff AM, et al. *Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.* N Engl J Med. 2023;389:514-526.
2. Retatrutide Phase 2 Trial — New England Journal of Medicine.
3. Retatrutide and metabolic disease clinical-trial research.

Note: BehemothLabz does not sell this product. Purchase links on this page may direct to third-party suppliers through affiliate links.